| 0 (0%) | 11-11 15:57 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.06 | 1-year : | 9.13 |
| Resists | First : | 6.9 | Second : | 7.82 |
| Pivot price | 6.19  |
|||
| Supports | First : | 5.42 | Second : | 4.51 |
| MAs | MA(5) : | 6.03 |
MA(20) : | 6.23 |
| MA(100) : | 7.28 |
MA(250) : | 10.77 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 18.8 |
D(3) : | 15.7 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 20.75 | Low : | 5.42 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CAPR ] has closed above bottom band by 49.9%. Bollinger Bands are 64.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.27 - 6.31 | 6.31 - 6.35 |
| Low: | 5.36 - 5.39 | 5.39 - 5.42 |
| Close: | 5.51 - 5.57 | 5.57 - 5.62 |
Tue, 11 Nov 2025
How to read the order book for CAPR - 2025 Key Highlights & Weekly High Return Opportunities - newser.com
Tue, 11 Nov 2025
Capricor Therapeutics (CAPR) Awaits Key Trial Results for Duchenne Treatment - GuruFocus
Tue, 11 Nov 2025
Capricor Therapeutics Inc (CAPR) Q3 2025 Earnings Call Highlights: Navigating Challenges and ... - Yahoo Finance
Mon, 10 Nov 2025
Capricor Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Mon, 10 Nov 2025
Capricor: Q3 Earnings Snapshot - San Francisco Chronicle
Mon, 10 Nov 2025
Capricor (CAPR) Nears Critical Milestone with Phase 3 Trial of D - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 46 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 30.4 (%) |
| Shares Short | 12,250 (K) |
| Shares Short P.Month | 12,150 (K) |
| EPS | -1.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.29 |
| Profit Margin | 0 % |
| Operating Margin | -548.2 % |
| Return on Assets (ttm) | -53.5 % |
| Return on Equity (ttm) | -120.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.18 |
| Sales Per Share | 0.29 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -28 (M) |
| PE Ratio | -3.9 |
| PEG Ratio | 0 |
| Price to Book value | 2.69 |
| Price to Sales | 21.13 |
| Price to Cash Flow | -5.35 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|